相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma
Jie Gao et al.
BIOMATERIALS (2012)
The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes
Jie Gao et al.
BIOMATERIALS (2011)
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Alina Shapira et al.
DRUG RESISTANCE UPDATES (2011)
Nanomedicine for oral chemotherapy
Si-Shen Feng et al.
NANOMEDICINE (2011)
Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment
Edward K. Chow et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Antibody engineering promotes nanomedicine for cancer treatment
Jie Gao et al.
NANOMEDICINE (2010)
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress
Xiaowei Dong et al.
NANOMEDICINE (2010)
Lipid-based systemic delivery of siRNA
Yu-Cheng Tseng et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells
Sunita Yadav et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles
Xiang Rong Song et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations To Overcome Multidrug Resistance in Tumor Cells
Srinivas Ganta et al.
MOLECULAR PHARMACEUTICS (2009)
Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells
Alex M. Chen et al.
SMALL (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Mechanisms of disease - Cancer stem cells
Craig T. Jordan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
PL Greenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
AM Shannon et al.
CANCER TREATMENT REVIEWS (2003)
Targeting ceramide metabolism - a strategy for overcoming drug resistance
A Sanchenkov et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
分享论文
